Journal: Inflammatory bowel diseases

Article Title: Aberrant Mucin Expression Profiles Associate With Pediatric Inflammatory Bowel Disease Presentation and Activity.

doi: 10.1093/ibd/izac217

Figure Lengend Snippet: Figure 1. Expression of mucins in the colon of pediatric inflammatory bowel disease (IBD) patients and non-IBD control subjects. A, Relative messenger RNA (mRNA) expression of MUC1, MUC2, MUC3A, MUC3B, MUC4, and MUC13 in inflamed and noninflamed colonic tissue of IBD patients and non-IBD control subjects. Significant differences are indicated by *P < .05; **P < .01; ***P < .001 (1-way analysis of variance or Kruskal-Wallis, Tukey ,and Dunn multiple comparison post hoc test). B, Immunohistochemical analysis of MUC1, MUC2, MUC3, MUC4, and MUC13 expression in colonic biopsies from non-IBD control subjects and IBD patients. Representative images were selected. Scale bars = 20 μm.

Article Snippet: Five-micrometer cross-sections were deparaffinized, rehydrated, and used for immunohistochemical stainings using target specific primary antibodies and visualization with a secondary streptavidin–horseradish peroxidaseconjugated antibody and AEC (3-amino-9-ethylcarbazole) substrate to detect the expression and localization of MUC1 (AF6298; R&D systems; 1:500), MUC2 (NBP1-31,231; Novus Biologicals; 1:2000), MUC3 (NBP2-44,434; Novus Biologicals; 1:100), MUC4 (NBP1-52193; Novus Biologicals; 1:3000), and MUC13 (MABC209; Merck Millipore; 1:1000).

Techniques: Expressing, Control, Comparison, Immunohistochemical staining

Journal: Immunity, Inflammation and Disease

Article Title: Alleviating effect of Nexrutine on mucosal inflammation in mice with ulcerative colitis: Involvement of the RELA suppression

doi: 10.1002/iid3.1147

Figure Lengend Snippet: Nexrutine alleviates inflammation and colonic mucosal barrier damage in mice with UC. A mouse model of UC was induced by administration of 3% DSS in drinking water. The model mice were treated with Nexrutine (300 mg/kg or 600 mg/kg) or the positive control regimen Mesalazine (195 mg/kg). (A) Body weight change of mice in each group; (B) DAI score of mice in each group; (C) length of whole colon of mice in each group; (D) pathological injury score in mouse colon tissues evaluated by HE staining; (E) concentrations of IL‐1β, IL‐6, TNF‐α, and IL‐10 in mouse colon tissues analyzed by ELISA kits; (F) expression of MUC3, Claudin‐1, and ZO‐1 in mouse colon tissues determined by IHC assay. In each group, n = 8. Differences were analyzed by the one‐way (B, C, D) or two‐way (A, E, F) ANOVA. * p < .05 versus the control group; # p < .05 versus the DSS group. DAI, disease activity index; DSS, dextran sulfate sodium; HE, hematoxylin and eosin; IHC, immunohistochemistry; UC, ulcerative colitis.

Article Snippet: Subsequently, the sections were incubated with antibodies of mucin 3 (MUC3; 1:500, PAB031Mu01; Cloud‐Clone Corp.), Claudin‐1 (1:500, ab211737; Abcam Inc.), and tight junction protein 1 (ZO‐1, 1:500, ab276131; Abcam) overnight at 4°C, followed by incubation with goat anti‐rabbit IgG (1: 1,000, ab6721; Abcam) at 37°C for 20 min.

Techniques: Positive Control, Staining, Enzyme-linked Immunosorbent Assay, Expressing, Activity Assay, Immunohistochemistry

Journal: Immunity, Inflammation and Disease

Article Title: Alleviating effect of Nexrutine on mucosal inflammation in mice with ulcerative colitis: Involvement of the RELA suppression

doi: 10.1002/iid3.1147

Figure Lengend Snippet: Restoration of RELA aggravates inflammatory injury in mouse colon tissues. Mice were injected with Ad‐RELA through the mesenteric artery, followed by the 3% DSS and Nexrutine (300 mg/kg) treatments. (A) Body weight change of mice in each group; (B) DAI score of mice in each group; (C) length of whole colon of mice in each group; (D) pathological injury score in mouse colon tissues evaluated by HE staining; (E) concentrations of IL‐1β, IL‐6, TNF‐α, and IL‐10 in mouse colon tissues analyzed by ELISA kits; (F) expression of MUC3, Claudin‐1, and ZO‐1 in mouse colon tissues determined by IHC assay. In each group, n = 8. Differences were analyzed by the unpaired t test (B–D) or two‐way ANOVA (A, E, F). * p < .05 versus the control group; # p < .05 versus the DSS group. DAI, disease activity index; DSS, dextran sulfate sodium; HE, hematoxylin and eosin; IHC, immunohistochemistry.

Article Snippet: Subsequently, the sections were incubated with antibodies of mucin 3 (MUC3; 1:500, PAB031Mu01; Cloud‐Clone Corp.), Claudin‐1 (1:500, ab211737; Abcam Inc.), and tight junction protein 1 (ZO‐1, 1:500, ab276131; Abcam) overnight at 4°C, followed by incubation with goat anti‐rabbit IgG (1: 1,000, ab6721; Abcam) at 37°C for 20 min.

Techniques: Injection, Staining, Enzyme-linked Immunosorbent Assay, Expressing, Activity Assay, Immunohistochemistry